ICADE (ICAD.PA)

FR0000035081 - REIT

26.9  -0.56 (-2.04%)

Fundamental Rating

4

Overall ICAD gets a fundamental rating of 4 out of 10. We evaluated ICAD against 45 industry peers in the Diversified REITs industry. ICAD has a bad profitability rating. Also its financial health evaluation is rather negative. ICAD has a correct valuation and a medium growth rate. Finally ICAD also has an excellent dividend rating.



3

1. Profitability

1.1 Basic Checks

ICAD had positive earnings in the past year.
In the past year ICAD had a positive cash flow from operations.
ICAD had positive earnings in 4 of the past 5 years.
Each year in the past 5 years ICAD had a positive operating cash flow.

1.2 Ratios

ICAD has a Return On Assets of -8.83%. This is amonst the worse of the industry: ICAD underperforms 88.10% of its industry peers.
With a Return On Equity value of -21.52%, ICAD is not doing good in the industry: 90.48% of the companies in the same industry are doing better.
ICAD has a Return On Invested Capital of 1.61%. This is amonst the worse of the industry: ICAD underperforms 83.33% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ICAD is in line with the industry average of 3.43%.
Industry RankSector Rank
ROA -8.83%
ROE -21.52%
ROIC 1.61%
ROA(3y)-2.74%
ROA(5y)-1.07%
ROE(3y)-6.1%
ROE(5y)-1.52%
ROIC(3y)2.98%
ROIC(5y)2.88%

1.3 Margins

With a Operating Margin value of 10.13%, ICAD is not doing good in the industry: 85.71% of the companies in the same industry are doing better.
ICAD's Operating Margin has improved in the last couple of years.
The Profit Margin and Gross Margin are not available for ICAD so they could not be analyzed.
Industry RankSector Rank
OM 10.13%
PM (TTM) N/A
GM N/A
OM growth 3Y-26.2%
OM growth 5Y5.52%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICAD is destroying value.
ICAD has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for ICAD has been increased compared to 5 years ago.
Compared to 1 year ago, ICAD has a worse debt to assets ratio.

2.2 Solvency

ICAD has an Altman-Z score of 0.88. This is a bad value and indicates that ICAD is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 0.88, ICAD perfoms like the industry average, outperforming 52.38% of the companies in the same industry.
ICAD has a debt to FCF ratio of 47.43. This is a negative value and a sign of low solvency as ICAD would need 47.43 years to pay back of all of its debts.
ICAD has a worse Debt to FCF ratio (47.43) than 80.95% of its industry peers.
A Debt/Equity ratio of 1.07 is on the high side and indicates that ICAD has dependencies on debt financing.
ICAD's Debt to Equity ratio of 1.07 is on the low side compared to the rest of the industry. ICAD is outperformed by 78.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF 47.43
Altman-Z 0.88
ROIC/WACC0.5
WACC3.2%

2.3 Liquidity

A Current Ratio of 2.04 indicates that ICAD has no problem at all paying its short term obligations.
ICAD has a better Current ratio (2.04) than 95.24% of its industry peers.
A Quick Ratio of 1.69 indicates that ICAD should not have too much problems paying its short term obligations.
With an excellent Quick ratio value of 1.69, ICAD belongs to the best of the industry, outperforming 90.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.04
Quick Ratio 1.69

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 148.29% over the past year.
Measured over the past years, ICAD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -11.35% on average per year.
ICAD shows a small growth in Revenue. In the last year, the Revenue has grown by 1.13%.
The Revenue has been decreasing by -1.33% on average over the past years.
EPS 1Y (TTM)148.29%
EPS 3Y-15.89%
EPS 5Y-11.35%
EPS Q2Q%0.16%
Revenue 1Y (TTM)1.13%
Revenue growth 3Y4.78%
Revenue growth 5Y-1.33%
Sales Q2Q%285.92%

3.2 Future

Based on estimates for the next years, ICAD will show a small growth in Earnings Per Share. The EPS will grow by 5.41% on average per year.
ICAD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 46.06% yearly.
EPS Next Y23.6%
EPS Next 2Y6.42%
EPS Next 3Y2.54%
EPS Next 5Y5.41%
Revenue Next Year-20.99%
Revenue Next 2Y-12.05%
Revenue Next 3Y-7.2%
Revenue Next 5Y46.06%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

6

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 9.51, the valuation of ICAD can be described as very reasonable.
85.71% of the companies in the same industry are more expensive than ICAD, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 30.45. ICAD is valued rather cheaply when compared to this.
With a Price/Forward Earnings ratio of 8.42, the valuation of ICAD can be described as very reasonable.
ICAD's Price/Forward Earnings ratio is rather cheap when compared to the industry. ICAD is cheaper than 83.33% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of ICAD to the average of the S&P500 Index (21.99), we can say ICAD is valued rather cheaply.
Industry RankSector Rank
PE 9.51
Fwd PE 8.42

4.2 Price Multiples

83.33% of the companies in the same industry are more expensive than ICAD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ICAD is valued a bit more expensive than 73.81% of the companies in the same industry.
Industry RankSector Rank
P/FCF 20.3
EV/EBITDA 12.25

4.3 Compensation for Growth

ICAD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.4
PEG (5Y)N/A
EPS Next 2Y6.42%
EPS Next 3Y2.54%

7

5. Dividend

5.1 Amount

ICAD has a Yearly Dividend Yield of 19.64%, which is a nice return.
ICAD's Dividend Yield is rather good when compared to the industry average which is at 7.57. ICAD pays more dividend than 95.24% of the companies in the same industry.
ICAD's Dividend Yield is rather good when compared to the S&P500 average which is at 2.26.
Industry RankSector Rank
Dividend Yield 19.64%

5.2 History

The dividend of ICAD has a limited annual growth rate of 0.17%.
Dividend Growth(5Y)0.17%
Div Incr Years1
Div Non Decr Years1

5.3 Sustainability

ICAD has negative earnings and hence a negative payout ratio. The dividend may be in danger.
The dividend of ICAD is growing, but earnings are growing more, so the dividend growth is sustainable.
DP-36.7%
EPS Next 2Y6.42%
EPS Next 3Y2.54%

ICADE

EPA:ICAD (9/18/2024, 7:00:00 PM)

26.9

-0.56 (-2.04%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.04B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 19.64%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 9.51
Fwd PE 8.42
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.4
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.83%
ROE -21.52%
ROCE
ROIC
ROICexc
ROICexgc
OM 10.13%
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 1.07
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.04
Quick Ratio 1.69
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)148.29%
EPS 3Y-15.89%
EPS 5Y
EPS Q2Q%
EPS Next Y23.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.13%
Revenue growth 3Y4.78%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y